X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1530) 1530
Newspaper Article (157) 157
Newsletter (140) 140
Publication (125) 125
Book Review (43) 43
Transcript (20) 20
Book Chapter (18) 18
Magazine Article (18) 18
Book / eBook (7) 7
Trade Publication Article (5) 5
Conference Proceeding (3) 3
Data Set (2) 2
Dissertation (1) 1
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1034) 1034
index medicus (995) 995
angiogenesis (818) 818
cancer (446) 446
angiogenesis inhibitors - therapeutic use (445) 445
angiogenesis inhibitors (439) 439
female (426) 426
animals (389) 389
bevacizumab (376) 376
male (365) 365
vascular endothelial growth factor (335) 335
care and treatment (319) 319
research (304) 304
oncology (283) 283
angiogenesis inhibitors - economics (261) 261
ophthalmology (256) 256
aged (248) 248
ranibizumab (242) 242
macular degeneration (236) 236
metastasis (232) 232
vascular endothelial growth factor a - antagonists & inhibitors (226) 226
middle aged (213) 213
endothelial growth-factor (206) 206
angiogenesis inhibitors - administration & dosage (200) 200
medicine (199) 199
health aspects (190) 190
chemotherapy (178) 178
mice (176) 176
treatment outcome (171) 171
analysis (166) 166
intravitreal injections (163) 163
research article (162) 162
tumors (152) 152
clinical trials (151) 151
studies (148) 148
expression (147) 147
multidisciplinary sciences (144) 144
proteins (143) 143
antibodies, monoclonal, humanized (141) 141
therapy (139) 139
pharmacology & pharmacy (137) 137
macular degeneration - drug therapy (136) 136
aged, 80 and over (134) 134
cost-benefit analysis (134) 134
drug therapy (134) 134
pharmaceutical industry (133) 133
gene expression (132) 132
inflammation (127) 127
review (127) 127
science (126) 126
apoptosis (124) 124
antibodies, monoclonal, humanized - therapeutic use (123) 123
cancer therapies (123) 123
patients (119) 119
antibodies, monoclonal - therapeutic use (114) 114
physiological aspects (114) 114
kinases (113) 113
angiogenesis inhibitors - adverse effects (111) 111
adult (109) 109
medical research (108) 108
signal transduction (104) 104
vegf (103) 103
angiogenesis inhibitors - pharmacology (102) 102
neovascularization (102) 102
medicine, research & experimental (101) 101
wet macular degeneration - drug therapy (101) 101
breast cancer (100) 100
diabetes (100) 100
growth factors (100) 100
stem cells (100) 100
retrospective studies (99) 99
rodents (98) 98
development and progression (97) 97
diabetic retinopathy (97) 97
food science & technology (97) 97
colorectal cancer (94) 94
drug costs (94) 94
usage (94) 94
in-vitro (92) 92
antibodies, monoclonal - economics (91) 91
antineoplastic agents - therapeutic use (88) 88
biology (88) 88
cytokines (88) 88
visual acuity (87) 87
antibodies, monoclonal, humanized - economics (84) 84
disease (84) 84
cell biology (80) 80
eye diseases (80) 80
article (77) 77
growth (77) 77
medicine, general & internal (76) 76
risk factors (76) 76
age (75) 75
cells (75) 75
genetic aspects (74) 74
wound healing (74) 74
cell line, tumor (73) 73
antineoplastic combined chemotherapy protocols - therapeutic use (72) 72
surgery (71) 71
abridged index medicus (70) 70
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1858) 1858
French (7) 7
German (7) 7
Spanish (4) 4
Swedish (3) 3
Chinese (2) 2
Czech (2) 2
Portuguese (2) 2
Hebrew (1) 1
Italian (1) 1
Japanese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the National Cancer Institute, ISSN 0027-8874, 3/2010, Volume 102, Issue 5, pp. 298 - 306
Journal Article
Journal Article
JAMA Ophthalmology, ISSN 2168-6165, 01/2016, Volume 134, Issue 1, pp. 95 - 99
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 68, Issue 3, pp. 516 - 522
Abstract Background Limited data exist on the economic consequences of implementing targeted therapy (TT) for metastatic renal cell carcinoma (RCC) in a... 
Urology | Metastatic renal cell carcinoma | Economic analysis | Population-based | Observational | National | Targeted therapy | Cost analysis | Implementation | 1ST-LINE TREATMENT | COST-EFFECTIVENESS | FINLAND | EVEROLIMUS | SUNITINIB MALATE | CANCER | INTERFERON-ALPHA | IMMUNOTHERAPY | 2ND-LINE TREATMENT | UROLOGY & NEPHROLOGY | Bevacizumab - therapeutic use | Everolimus - economics | Radiotherapy - economics | Humans | Middle Aged | Niacinamide - economics | Male | Antineoplastic Agents - therapeutic use | Efficiency | Employment - economics | Aged, 80 and over | Sirolimus - economics | Indoles - economics | Bevacizumab - economics | Costs and Cost Analysis | Protein Kinase Inhibitors - economics | Niacinamide - therapeutic use | Antineoplastic Agents - economics | Carcinoma, Renal Cell - economics | Indoles - therapeutic use | Ambulatory Care - economics | Phenylurea Compounds - economics | Drug Costs | Niacinamide - analogs & derivatives | Fluorouracil - economics | Interleukin-2 - economics | Interleukin-2 - therapeutic use | Immunologic Factors - economics | Fluorouracil - therapeutic use | Neoplasm Metastasis - drug therapy | Angiogenesis Inhibitors - therapeutic use | Adult | Angiogenesis Inhibitors - economics | Everolimus - therapeutic use | Female | Registries | Pyrroles - economics | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Radiography - economics | Interferon-alpha - therapeutic use | Interferon-alpha - economics | Phenylurea Compounds - therapeutic use | Kidney Neoplasms - economics | Health Care Costs | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Denmark | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Hospitalization - economics | Immunologic Factors - therapeutic use | Economic aspects | Metastasis | Carcinoma, Renal cell
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2018, Volume 13, Issue 5, p. e0197670
Background The discussion on the use of bevacizumab is still ongoing and often doctors are deterred from using bevacizumab due to legal or political issues.... 
EYE | VISUAL-ACUITY | INTRAVITREAL RANIBIZUMAB | CLINICAL-TRIAL | EFFICACY | UK | MULTIDISCIPLINARY SCIENCES | QUALITY-OF-LIFE | MODEL | OUTCOMES | Drug Costs | Recombinant Fusion Proteins - economics | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Intravitreal Injections | Humans | Recombinant Fusion Proteins - therapeutic use | Drug Approval | Ranibizumab - therapeutic use | Off-Label Use - economics | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Macular Degeneration - economics | Macular Degeneration - drug therapy | Cost Savings | Angiogenesis Inhibitors - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - economics | Bevacizumab - economics | Recombinant Fusion Proteins - administration & dosage | Quality-Adjusted Life Years | Bevacizumab - administration & dosage | Drug Administration Schedule | Europe | Decision Support Techniques | Treatment Outcome | Visual Acuity | Receptors, Vascular Endothelial Growth Factor - administration & dosage | Health Care Costs | Cost-Benefit Analysis | Ranibizumab - administration & dosage | Ranibizumab - economics | Macular degeneration | Drug therapy | Analysis | Medical care, Cost of | Drugs | Medical personnel | Medical services | Injection | Patients | Age related diseases | Doctors | Bevacizumab | Quality of life | Vision | Expenditures | Ophthalmology | Clinical medicine | Cost analysis | Vascular endothelial growth factor | Age | Overspending
Journal Article
Journal Article
Journal Article
British Journal of Ophthalmology, ISSN 0007-1161, 08/2015, Volume 99, Issue 8, pp. 1055 - 1059
Journal Article
Journal Article